Blog
About

36
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Madecassoside impedes invasion of rheumatoid fibroblast-like synoviocyte from adjuvant arthritis rats via inhibition of NF-κB-mediated matrix metalloproteinase-13 expression

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fibroblast-like synoviocytes (FLS) play a pivotal role in Rheumatoid arthritis (RA) pathogenesis through aggressive migration and invasion. Madecassoside (Madec), a triterpenoid saponin present in Centella asiatica herbs, has a potent anti-inflammatory effect. In the present study, Madec exerted an obvious therapeutic effect in reversing the histological lesions in adjuvant-induced arthritis (AIA) rats. To recognize the anti-rheumatoid potentials of Madec, we further investigated whether Madec interfered with FLS invasion and metalloproteinase (MMP) expression. In cultures of primary FLS isolated from the AIA rats, Madec (10 and 30 μmol·L –1) was proven to considerably inhibit migration and invasion of FLS induced by interleukin 10 (IL-10), but exhibiting no obvious effect on cell proliferation. Madec repressed IL-10-triggered FLS invasion by prohibiting the expression of MMP-13. Additionally, Madec suppressed MMP-13 transcription via inhibiting the MMP-13 promoter-binding activity of NF- κB. Our results further showed that Madec down-regulated the translocation and phosphorylation of NF- κB as demonstrated by Western blotting and immunofluorescence assays. In conclusion, our results suggest that Madec exerts anti-RA activity via inhibiting the NF- κB /MMP-13 pathway.

          Related collections

          Author and article information

          Journal
          CJNM
          Chinese Journal of Natural Medicines
          Elsevier
          1875-5364
          20 May 2018
          : 16
          : 5
          : 330-338
          Affiliations
          1Department of Orthopedics Lesion 2, Shijiazhuang No.1 Hospital, Shijiazhuang 050000, China
          2Department of Orthopedics Lesion Spine, Third Hospital of Hebei Medical University, Shjiazhuang 050000, China
          Author notes
          *Corresponding author: SHEN Yong, Tel: +86-311-87023626, Fax: +86-31187023626, E-mail: shenyongdrug@ 123456126.com

          These authors have no conflict of interest to declare.

          Article
          S1875-5364(18)30064-5
          10.1016/S1875-5364(18)30064-5
          Copyright © 2018 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

          Comments

          Comment on this article